Core Viewpoint - Dentsply Sirona will host an investor conference call on November 6, 2025, to discuss its financial results for Q3 of fiscal year 2025 [1]. Group 1: Conference Call Details - The conference call is scheduled for 8:30 am ET on November 6, 2025 [1]. - A live webcast will be available on the Investors section of the Company's website [2]. - Participants are required to register for the call, and a replay of the webcast will be accessible afterward [2]. Group 2: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies globally [3]. - The Company has over a century of innovation and service in the dental industry [3]. - Dentsply Sirona offers a comprehensive range of dental and oral health products, along with other consumable medical devices [3]. - The Company is headquartered in Charlotte, North Carolina, and its shares are listed on Nasdaq under the symbol XRAY [3].

Core Viewpoint - Dentsply Sirona has appointed Aldo M. Denti as Executive Vice President and Chief Commercial Officer to enhance customer focus and streamline operations within the company [1][3]. Group 1: Appointment Details - Aldo M. Denti will assume the role of Executive Vice President and Chief Commercial Officer effective October 6, 2025 [1]. - The appointment aims to align Global Business Units and Commercial Organizations to improve operational efficiency and customer experience [1][3]. Group 2: Aldo M. Denti's Background - Mr. Denti has over 25 years of experience in the Medical Device and Consumer Health sectors, with a strong track record in sales, marketing, and strategic planning [2][4]. - He previously served as Company Group Chairman, Global Orthopedics, at Johnson & Johnson Medtech, contributing to transformative growth [2][4]. Group 3: Company Strategy and Goals - The new CCO role is expected to strengthen collaboration across business units, unlock synergies, and support global revenue growth [3]. - Dentsply Sirona aims to leverage its diverse product portfolio to enhance customer satisfaction and drive superior growth and profitability [3]. Group 4: Company Overview - Dentsply Sirona is the largest diversified manufacturer of professional dental products and technologies, with a history of over a century in the dental industry [5]. - The company develops and markets a comprehensive range of dental and oral health products, focusing on high-quality and effective solutions for patient care [5].

Core Insights - Investors are increasingly turning to dividend-yielding stocks during market turbulence, as these companies typically have high free cash flows and offer substantial dividend payouts [1] Company Summaries GSK plc (NYSE:GSK) - Dividend Yield: 4.13% - Jefferies analyst Peter Welford downgraded the stock from Buy to Hold on Nov. 12, 2024, with an accuracy rate of 57% [7] - Guggenheim analyst Seamus Fernandez downgraded the stock from Buy to Neutral on Oct. 31, 2024, with an accuracy rate of 73% [7] - Recent News: Luke Miels appointed as CEO Designate, effective Jan. 1, 2026 [7] DENTSPLY SIRONA Inc (NASDAQ:XRAY) - Dividend Yield: 5.04% - UBS analyst Kevin Caliendo maintained a Buy rating but reduced the price target from $25 to $24 on Aug. 8, 2025, with an accuracy rate of 67% [7] - Stifel analyst Jonathan Block maintained a Hold rating and cut the price target from $19 to $17 on Aug. 8, 2025, with an accuracy rate of 71% [7] - Recent News: Decision to retain Wellspect Healthcare after a strategic review on Sept. 8 [7] Bristol-Myers Squibb Company (NYSE:BMY) - Dividend Yield: 5.62% - Citigroup analyst Andrew Baum maintained a Neutral rating and lowered the price target from $51 to $47 on Aug. 1, 2025, with an accuracy rate of 69% [7] - Morgan Stanley analyst Terence Flynn maintained an Underweight rating and reduced the price target from $36 to $34 on July 10, 2025, with an accuracy rate of 63% [7] - Recent News: Announced results from the Phase 3 EXCALIBER-RRMM study on Sept. 23, evaluating iberdomide in combination with standard therapies for multiple myeloma [7]

Core Insights - Dentsply Sirona has integrated Pearl's Second Opinion dental AI capabilities into its cloud-based DS Core imaging software [1] Company Developments - The addition of Pearl's AI technology aims to enhance the diagnostic capabilities of Dentsply Sirona's imaging solutions [1] - This integration reflects a growing trend in the dental industry towards the adoption of artificial intelligence to improve patient outcomes and operational efficiency [1] Industry Trends - The dental industry is increasingly leveraging AI technologies to streamline processes and enhance diagnostic accuracy [1] - The collaboration between Dentsply Sirona and Pearl signifies a shift towards more technologically advanced solutions in dental care [1]

Core Insights - DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is recognized for its significant upside potential and is included in the list of the 15 Best Robotics Stocks to Buy under $20 [1] Strategic Roadmap - At the Morgan Stanley 23rd Annual Global Healthcare Conference, DENTSPLY SIRONA's leadership presented a refined strategy roadmap focusing on decision-making speed, resource allocation to R&D and sales, and increasing U.S. market penetration ahead of future product launches [2][3] - The company aims for above 19% fiscal 2025 margins and $300–400 million in annual cash flow, with a target of $3 EPS for 2026, while forecasting a 2%–4% decline in organic revenue for 2025 and an annual tariff impact of $80 million [3] Operational Improvements - Management acknowledged challenges in implementing ERP but emphasized enhancing customer satisfaction, expanding direct distribution channels, and considering bolt-on acquisitions to increase the total addressable market [4] Business Segments - DENTSPLY SIRONA operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare, providing cloud-enabled dental tools, supplies, and healthcare solutions globally [5]

Company Overview - DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is the world's largest manufacturer of professional dental products and technologies, operating in various segments including imaging, CAD/CAM, endodontics, restoratives, and healthcare consumables through its Wellspect unit [2][3]. Strategic Decisions - The company recently completed a strategic review of Wellspect Healthcare and opted to retain the unit, citing strong growth prospects and innovative products like LoFric catheters, as well as significant untapped market potential in global continence care [3][4]. - CEO Dan Scavilla emphasized that recent investments in Wellspect are leading to solid organic sales growth, and the unit's recurring cash flows will support further innovation across the dental and healthcare sectors [3]. Market Position and Growth Potential - DENTSPLY SIRONA has garnered attention as a cheap healthcare stock due to its combination of recurring revenue and innovation, which provides both stability and growth potential [4]. - The company showcased its latest developments at major healthcare conferences in September 2025, including the Morgan Stanley Global Healthcare Conference and the Baird Global Healthcare Conference, highlighting its commitment to integrated dental technologies [4].

Key Takeaways XRAY's review concluded that retaining Wellspect offers more value than a sale.XRAY concludes that Wellspect leads in continence care with steady growth and strong cash flows.Wellspect's $2B market and pipeline back XRAY's long-term profitability strategy.Dentsply Sirona (XRAY) recently concluded that retaining the Wellspect business portfolio is likely to create more value for its stockholders compared to other strategic alternatives. CEO Dan Scavilla emphasized that, after a comprehensive st ...

PresentationJeffrey JohnsonSenior Research Analyst All right. Good afternoon. Why don't we get started? My name is Jeff Johnson. I'm the senior medical technology analyst at Baird. Our next presentation this afternoon is from Dentsply Sirona, a leading manufacturer of dental consumables and equipment across the globe. With us today from Dentsply, we're happy to have CFO, Matt Garth. Matt, I think you said we can just go straight into Q&A. ...

Summary of Dentsply Sirona Conference Call Company Overview - **Company**: Dentsply Sirona (NasdaqGS: XRAY) - **Industry**: Dental consumables and equipment manufacturing Key Points and Arguments 1. **Management Changes and Focus**: New management is prioritizing the recovery of the U.S. business and reallocating resources to enhance innovation and sales force effectiveness [7][8][10] 2. **R&D Investment Increase**: R&D spending is set to increase from approximately 4% to 7%, indicating a significant opportunity for innovation and product development [7][10][12] 3. **Essential Dental Solutions (EDS)**: EDS, which constitutes about 40% of revenue, is identified as a key area for investment, particularly in general dental consumables and restorative products [10][16] 4. **Margin Improvement Strategy**: The company aims to improve operating margins by reducing SG&A expenses and focusing on value-accretive roles, with a target to bring SG&A down to around 30% [21][25] 5. **Market Growth Outlook**: The company anticipates market growth rates of 2% to 3% for EDS and mid-single digits for other segments, emphasizing the need for Dentsply Sirona to align with market growth [67][70] 6. **Competitive Positioning**: Dentsply Sirona acknowledges past share losses to competitors and emphasizes the need for innovation and resource allocation to regain competitiveness in the implant market [70][72] 7. **Customer Experience Focus**: Enhancing customer experience is a priority, with a commitment to improving relationships with distributors and partners [32][54] 8. **ERP Integration**: The company is undergoing ERP integration, which is expected to yield synergies and cost savings in the long term [60][62] 9. **Free Cash Flow Management**: The management is focused on increasing free cash flow and aims for consistent EPS growth through share repurchase programs [103] Additional Important Insights - **Leadership Philosophy**: The new leadership emphasizes a disciplined approach to decision-making and resource allocation, aiming for long-term growth rather than short-term gains [20][64] - **Ecosystem Strategy**: Dentsply Sirona is positioning itself to leverage a comprehensive suite of dental technologies, enhancing value creation for dental practices and DSOs [90][91] - **Turnaround Efforts**: The management is committed to a turnaround strategy that includes operational efficiencies and a focus on core competencies [64][70] This summary encapsulates the critical insights from the Dentsply Sirona conference call, highlighting the company's strategic direction, investment priorities, and market outlook.

PresentationErin Wilson WrightEquity Analyst Good afternoon, everyone. My name is Erin Wright, the health care services analyst at Morgan Stanley. We're happy to have with us Dentsply Sirona and the management team. We have CEO, Dan Scavilla, if I said that right, and Matt Garth, the CFO. Newly appointed management team is here. So we're really excited to have you here and give your views on the strategy and everything kind of going forward. But for more important disclosures, please see the Morgan Stanley ...